Neurontin, Gabapentin News

A class can't be decertified unless there are substantial changes to the facts of a case, nor can it be decertified once a partial ruling has been made as to the merits of the case, an attorney for a class suing over the off-label marketing of epilepsy and neuralgia drug Neurontin argued before the Pennsylvania Superior Court in Philadelphia ...

Astellas Pharma Inc. and XenoPort, Inc. today announced that a new drug application has been filed with the Pharmaceuticals and Medical Device Agency in Japan for ASP8825 , also known as XP13512, as a potential treatment for restless legs syndrome .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other ...

The Editorial that Wasn't: Evidence for Systematic Research Manipulation Undetectable by Critical Review Woe to those of us who have been advocates for evidence-based medicine.

Clinical trials are supposed to answer a specific, predetermined scientific question, but a comparison of Pfizer ... [ News Source ] Posted in Neurontin lawsuit

What? Pfizer fudged its studies in the NEJM? Neurontin might not be a drug for sexual problems, but this week's controversy surrounding it speaks volumes for the concerns I have about a number of the drug studies that I read in medical journals.

Susan Dudley, a nurse, became depressed and suicidal after taking a medication, prescribed to her for pain but not approved for such use.

The drug companies Pfizer and Parke-Davis shaded clinical trial results in at least 12 studies in order to make the drug gabapentin appear more effective for off-label use, says a report today in The New England Journal of Medicine .

An unusual look at internal documents from a pharmaceutical company suggests that clinical data was manipulated to make a popular anti-seizure drug, gabapentin , look more effective than it actually was, thereby increasing possibilities for its off-label usage, according to a new report.

Pfizer disputes the conclusions in a report in the New England Journal of Medicine that says results in company-funded studies of its epilepsy drug were fudged.

The U.S. Food and Drug Administration has extended its review of one of GlaxoSmithKline 's pain treatments.

The scariest wrinkle in the Omnicare kickback case is just how vulnerable old people in nursing homes are to schemes in which drug companies allegedly induce pharmacies to prescribe drugs they otherwise wouldn't. Download the complaint from the Phillips and Cohen web site .

Available studies were identified using a MEDLINE and EMBASE search. One hundred and five studies were included.

A single pill containing the pain relievers tramadol and acetaminophen is as effective as the drug gabapentin for treating diabetes-related nerve pain, according to study findings presented Tuesday at the 20th World Diabetes Congress in Montreal.

Crissie Elrick Photo Editori 1 2 cmelrick@valdosta.edu Gabapentin has been shown and celecoxib 200 mg lifelong disease and that.

Depomed announced earlier this week that its investigational non-hormonal therapeutic option for the treatment of menopausal hot flashes, Serada , failed to meet its primary efficacy endpoints in its two pivotal BREEZE clinical studies .

Using functional connectivity MRI brain scanning, scientists at Washington University and the University of Chieti, have discovered an alteration in the brain's spontaneous background activity after it has learned a new task.

Kerri Lynn is I'm getting very tired of not being able to do every day things, like lifting, i can't cook wash dishes or anything.I go to therapy 3x a week Living With It married, retired, active in home & church 10/14/09 Kerri Lynn Topics: Chronic Pain I had CRPS after a fall breaking my wrist.

Trading was a little thin due to the Columbus Day holiday Monday, and a breakdown in technical support levels caused some midsession panic, but the S&P 500 successfully logged its sixth straight gain- the best streak this year for the stock market.

U.S. medical researchers say they've identified a molecule that plays a key role in the formation of brain synapses.